Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
Baldin G, Ciccullo A, Rusconi S, Capetti A, Sterrantino G, Colafigli M, d'Ettorre G, Giacometti A, Cossu MV, Borghetti A, Gennari W, Mussini C, Borghi V, Di Giambenedetto S. Baldin G, et al. Among authors: rusconi s. Int J Antimicrob Agents. 2019 Dec;54(6):728-734. doi: 10.1016/j.ijantimicag.2019.09.002. Epub 2019 Sep 12. Int J Antimicrob Agents. 2019. PMID: 31521809 Free article.
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.
Bongiovanni M, Bini T, Tordato F, Cicconi P, Melzi S, Repetto D, Sollima S, Rusconi S, d'Arminio Monforte A. Bongiovanni M, et al. Among authors: rusconi s. J Antimicrob Chemother. 2003 Jan;51(1):171-4. doi: 10.1093/jac/dkg045. J Antimicrob Chemother. 2003. PMID: 12493805 Free article.
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. Among authors: rusconi s. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens.
Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Gonzalez de Requena D, et al. Among authors: rusconi s. J Antimicrob Chemother. 2011 Jan;66(1):192-200. doi: 10.1093/jac/dkq384. Epub 2010 Oct 29. J Antimicrob Chemother. 2011. PMID: 21037251 Free article.
421 results